淋巴瘤样肉芽肿的病理生物学与治疗
淋巴瘤样肉芽肿(LYG)是一种罕见的EBV驱动B细胞淋巴增殖性疾病,推测源于EBV免疫监视缺陷。病理按EBV阳性异型B细胞数量与密度分级,伴血管侵袭性/破坏性反应性T细胞浸润及不同程度坏死。临床几乎均累及肺部,淋巴结和骨髓受累极罕见。治疗依组织学分级选择:低级别用干扰素-α2b免疫调节,高级别需免疫化疗,难治或多次复发可考虑造血干细胞移植但疗效未明。
要点
- LYG几乎均累及肺部,淋巴结或骨髓受累极罕见,若出现应考虑其他诊断。
- 低级别LYG多为多克隆、免疫依赖,可用干扰素-α2b;高级别多为寡克隆或单克隆,需免疫化疗。
- 高级别经免疫化疗后可复发为低级别,低级别经免疫调节可进展为高级别,可用交叉治疗处理。
核心结论
- LYG是EBV驱动的B细胞淋巴增殖性疾病,治疗选择基于组织学分级与病理生物学。
研究设计与样本
- 本文为综述,讨论LYG的发病机制、组织病理与临床特征及治疗选择。
主要发现
- LYG推测由EBV免疫监视缺陷所致,多数患者有免疫功能障碍证据但无已知原发免疫缺陷。
- 病理分级依据EBV阳性异型B细胞的数量与密度,伴血管侵袭性/破坏性反应性T细胞浸润和不同程度坏死。
- 临床几乎均累及肺部,其他常见结外部位包括皮肤、中枢神经系统、肝和肾,淋巴结和骨髓受累极罕见。
关键数值与推荐
- 低级别LYG推测为免疫依赖、通常多克隆,高级别推测为免疫独立、通常寡克隆或单克隆。
- 低级别LYG增强EBV免疫应答的方法包括干扰素-α2b治疗,高级别疾病需免疫化疗。
- 原发难治或多次复发患者可考虑造血干细胞移植,但其疗效未充分确立。
临床怎么用
- 依据组织学分级选择治疗:低级别用免疫调节(如干扰素-α2b),高级别用免疫化疗。
- 注意分级间可相互转化,高级别复发为低级别或低级别进展为高级别时可用交叉治疗。
- 淋巴结或骨髓受累时应警惕并考虑其他EBV阳性B细胞淋巴增殖性疾病或淋巴瘤。
局限性
- 造血干细胞移植对原发难治或多次复发LYG的疗效未充分确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lymphomatoid granulomatosis (LYG) is a rare Epstein-Barr virus (EBV)-driven B-cell lymphoproliferative disease (LPD). This disease is hypothesized to result from defective immune surveillance of EBV, with most patients showing evidence of immune dysfunction, despite no known primary immunodeficiency. Pathologically, LYG is graded by the number and density of EBV+ atypical B cells, and other characteristic findings include an angioinvasive/angiodestructive reactive T-cell infiltrate and various degrees of necrosis. Clinically, LYG universally involves the lungs with other common extranodal sites, including skin, central nervous system, liver, and kidneys. Nodal and/or bone marrow involvement is extremely rare and, if present, suggests an alternative diagnosis. Treatment selection is based on histologic grade and underlying pathobiology with low-grade disease hypothesized to be immune-dependent and typically polyclonal and high-grade disease to be immune-independent and typically oligoclonal or monoclonal. Methods of augmenting the immune response to EBV in low-grade LYG include treatment with interferon-α2b, whereas high-grade disease requires immunochemotherapy. Given the underlying defective immune surveillance of EBV, patients with high-grade disease may have a recurrence in the form of low-grade disease after immunochemotherapy, and those with low-grade disease may progress to high-grade disease after immune modulation, which can be effectively managed with crossover treatment. In patients with primary refractory disease or in those with multiple relapses, hematopoietic stem cell transplantation may be considered, but its efficacy is not well established. This review discusses the pathogenesis of LYG and highlights distinct histopathologic and clinical features that distinguish this disorder from other EBV+ B-cell LPDs and lymphomas. Treatment options, including immune modulation and combination immunochemotherapy, are discussed.
引用
- Melani C, Jaffe ES, Wilson WH, et al. Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder. Blood. 2020. PMID: 32107539. doi:10.1182/blood.2019000933
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。